Cardiac remodeling and apoptosis before and after restoration of euthyroidism in Graves’ thyrotoxicosis  by Refaie, Wael et al.
The Egyptian Heart Journal (2012) 64, 75–80Egyptian Society of Cardiology
The Egyptian Heart Journal
www.elsevier.com/locate/ehj
www.sciencedirect.comORIGINAL ARTICLECardiac remodeling and apoptosis before and after
restoration of euthyroidism in Graves’ thyrotoxicosisWael Refaie a,*, Fawzya El Demerdash a, Ehsan Refaie b, Ahmed Elewa ca Department of Cardiology, Mansoura University, Egypt
b Department of Obstetric and Gynecology, Mansoura University, Egypt
c Department of Clinical Pathology, Mansoura University, Egypt
Available online 20 March 2012*
E
11
ho
Pe
doKEYWORDS
Cardiac remodeling;
Apoptosis;
Graves’ thyrotoxicosisCorresponding author.
-mail address: refaie_wael@
10-2608 ª 2012 Egyptian S
sting by Elsevier B.V. All rig
er review under responsibilit
i:10.1016/j.ehj.2012.02.001
Production and hyahoo.co
ociety of
hts reser
y of Egyp
osting by EAbstract Background: Thyrotoxicosis is usually associated with cardiovascular morphological
and functional changes (remodeling) which may lead to cardiac decompensation secondary to
the apoptotic process. Autoimmune initiation may be a triggering factor.
Aim: Identifying the structural and functional cardiac changes in Graves’ toxicosis before and after
restoration of euthyroidism and to illustrate the role of apoptosis if any on cardiac remodeling.
Study design: Prospective controlled study.
Subjects and methods: Thirty young females with Graves’ toxicosis and positive thyroid antibody
tests, were selected from outpatient clinics of Mansoura University Hospital. The studied cases were
evaluated by clinical examination, electrocardiography and echocardiography for cardiac changes
before and after restoration of the euthyroid state and compared to a control group of age and
sex matched euthyroid individuals. The anti apoptotic serum marker (Bcl-2) level was estimated
on inclusion and after control of the thyrotoxicosis. Correlation of the anti apoptotic serum marker
with thyroid function test and the cardiac remodeling changes was undertaken.
Results: Sinus tachycardia, prolonged QTc interval and increased QTd were evident. Echocardio-
graphic evidences of increased left ventricular mass, diastolic dysfunction and some systolic dys-
function were common and these positively correlated with thyroid function tests but negatively
correlated with serum anti apoptotic marker (Bcl-2).m (W. Refaie).
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76 W. Refaie et al.Conclusion: Structural cardiac and functional changes are usual ﬁndings in Graves’ toxicosis that
can be manifested by diastolic and systolic dysfunctional changes. Identifying remodeling and apop-
tosis and early management of thyrotoxicosis can halt the cardiac changes.
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Thyroid hormones have profound effects on virtually all tissues
and the cardiovascular (CV) system is a predominant one.1 Thy-
rotoxicosis has long been known to be associated with cardio-
megaly and heart failure (HF).2 Recent studies revealed the
presence of a ﬂow mediated type non-autoimmune form of a
reversible pulmonary hypertension (PHTN) in Graves’ toxicosis
(GT),3,4 and it is recommended to investigate thyroid status in
patients with right sidedHF especially in the presence of PHTN.5
About 6% of thyrotoxic patients develop symptoms of
heart failure and less than 1% develop a reversible form of di-
lated cardiomyopathy with biventricular or four chamber dila-
tation.6,7 The congestive heart failure occurring in Graves’
toxicosis in spite of the associated hyperdynamic circulation
could be due to direct damage by autoimmune myocarditis.8
Thyrotoxicosis may elicit acute myocardial ischemia even in
patients with angiographically normal coronary vessels. The
left ventricular apical akinesis and the impaired global systolic
function can be normalized by successful medical treatment of
thyrotoxicosis.9 Moreover, subclinical thyrotoxicosis may be
associated with changes in cardiac performance and morphol-
ogy with increased LV mass index, increased cardiac contrac-
tility with tachycardia, diastolic dysfunction, induction of
atrial arrhythmia and impaired cardiac performance.10
HF has become the dominant CV disorder worldwide and
there is an urgent need to clarify the mechanism covering path-
ological remodeling mediated through cell death and to iden-
tify the ways of preventing and treating HF.11 The
progression of compensated hypertrophy to HF is still de-
bated. The hypothesis that structural remodeling as well as cell
death, contribute to the transition to HF is accepted.12
There are 3 types of cell death (apoptosis, autophagy and
necrosis). Apoptosis is a form of programed cell death.
Autophagy is a cell survival mechanism that involves degrada-
tion and recycling of cytoplasmic components.11 The role of
apoptosis in heart during ischemic and non ischemic cardiomy-
opathies has been under investigation and reported to contrib-
ute to ventricular remodeling13 and studies on apoptosis have
proved new insights into autoimmune target destruction.
Apoptosis secondary to chronic remodeling is implicated as a
mediator to HF14 but there are still many controversies about
the presence and signiﬁcance of apoptosis in HF. These con-
troversies are partially attributed to the limitation of the tech-
nique used to detect apoptosis in HF.15
2. Aim
It was aimed to:
– Identify the cardiac structural and functional sequel of
Graves’ toxicosis;
– Correlation between thyroid function, electrocardiographic
and echocardiographic changes before and after medical
restoration of euthyroidism;– Illustrate the correlation between serum antiapoptotic fac-
tor (Bcl-2) and the cardiac changes.
3. Subjects and methods
Thirty young females (25–32 years) were selected from the med-
ical, endocrinal, cardiovascular and gynecology departments,
Mansoura Faculty of Medicine. Criteria for qualiﬁcation of
Graves’ disease included presence of goiter, ophthalmopathy
of any degree and symptoms and signs of thyrotoxicosis.
Thirty apparently age and body weight- matched healthy
females were included as a reference group. Neither the thyro-
toxic, nor the reference group were smokers, diabetics. None
had hypertension, kidney or liver disorders.
The clinical diagnosis of GT was conﬁrmed by the presence
of elevated FT3, FT4 and depressed sTSH besides the presence
of positive serum thyroid antibodies (TPOab, TSHRab). Preg-
nant, lactating women and those receiving hormonal contra-
ception, antithyroid, iodine containing drugs (expectorants,
amiodarone, lithium or radio contrast exposure) were ex-
cluded. Women with low Hb, low platelet count and/or leuco-
penia and those with elevated hepatic serum enzymes were also
excluded. Post-prandial serum glucose, serum urea, serum cre-
atinine and liver functions (serum bilirubin, AST, ALT and
ALP) were performed on automated analyzer Hitachi 911 Kits
supplied by Roche diagnostics.
Serum TSH concentration was measured by immunometric
assay. Serum free T3 and T4 were estimated using a solid phase
competitive chemiluminescent enzyme immunoassay. All thy-
roid hormone proﬁle were measured on Immunlite automated
analyzer. Serum thyroid hormones kits were supplied by DPC
(Diagnostic Products Corporation), Los Angeles, CA 90045-
5597. Serum B-cell lymphoma-2 antiapoptotic (Bcl-2) level kits
were supplied by IBL (Immuno-Biological Laboratories).
Clinical examination was performed stressing on history of
Palpitation and tachycardia. Cases with advanced Graves’ oph-
thalmopathy were not included as most of them were either un-
der corticosteroid therapies and/or immune modulating drugs.
A standard 12 lead ECG was recorded at 25 mm/s and 1 mV/
cm standardization, stressing on heart rate, rhythm, QTc and
QTd. Two-dimensional and Doppler echocardiography (para-
sternal and apical 4 chamber views) were undertaken.
The examined cases were advised rest with no undue effort
and to receive carbimazole 60 mg/day for 3 months with
clinical, CBC, serum hepatic enzymes every fortnight when
indicated. The studied thyroid function, the anti apoptotic
(Bcl-2) ECG and Echo-Doppler were reevaluated.4. Statistical analysis
Statistical analysis was performed by using SPSS statistical
package for Social Science Program version ‘‘10’’ 1999. Qual-
itative data were presented as frequency and percentages. The
Table 1 The clinical manifestation of the studied Grave’ toxicosis patients.
Before ttt No. of cases (%) After ttt No. of cases (%) P
Losing weight in spite of good appetite 24 cases (80) 3 cases (10) <0.001
Sense of hotness 22 cases (73.3) 2 cases (6.6) <0.001
Palpitation 22 cases (73.3) 3 cases (10) <0.001
Tachycardia 22 cases (73.3) 3 cases (10) <0.001
Menstrual irregularity 18 cases (60) 1 case (3.3) <0.001
Neck swelling 25 cases (83.3) 3 cases (10) <0.001
Table 2 Serum apoptotic marker (Bcl-2) level in thyrotoxicosis patients before and after treatment.
Parameter (mean ± SD) Control (C) Before ttt (B) After ttt (A) P
C vs B
P
C vs A
P
B vs A
Serum Bcl-2 (U/ml) 3.99 ± 2.9 24.80 ± 11.6 12.1 ± 26.7 <0.001 0.10 0.02
Table 3 ECG ﬁndings in Graves’ thyrotoxic patients before and after treatment.
Before ttt After ttt P
Sinus tachycardia 83.3% (25 cases) 10% (3 cases) <0.001
Voltage changes for LVH 26.6% (8 cases) 3.3% (one case) 0.02
QTc dispersion >80 ms 66.6% (20 cases) 10% (3 cases) <0.001
Prolonged QTc interval 66.6% (20 cases) 10% (3 cases) <0.001
Table 4 Correlation between serum Bcl-2 and LV diastolic function in Graves’ thyrotoxic patients before and after treatment.
Serum Bcl-2 before ttt Serum Bcl-2 after ttt P
Peak E velocity(cm/s) Before ttt r= 0.918 <0.001
After ttt r= 0.419 <0.001
Peak A velocity(cm/s) Before ttt r= 0.851 <0.001
After ttt r= 0.329 <0.01
Declaration time (ms) Before ttt r= 0.752 <0.001
After ttt r= 0.289 NS
Isovolumic relaxation time (ms) Before ttt r= 0.930 <0.001
After ttt r= 0.720 <0.001
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nov test to test for normal distribution of the data when para-
metric, expressed as mean and standard deviation. Student’s t
test was used, to test for difference in normally distributed
quantitative data between the two groups. Mann–Whitney-U
test was used for comparison between two groups when data
are not normally distributed. Signiﬁcance was considered when
P value less than 0.05.
5. Results
In the present study, ECG evidences of cardiac affection in-
cluded presence of signiﬁcant sinus tachycardia, prolonged
QTc and frequent QTd which were signiﬁcantly ameliorated
after treatment (Table 3).
The echocardiographic ﬁnding in GT before and after treat-
ment compared to the control group is illustrated in (Table 5),
which showed a signiﬁcant increase of both the interventricular
septum thickness at diastole (IVSD) and the posterior wallthickness at diastole (PWTD) in the GT group before treat-
ment compared to the control group. The increased thickness
of the IVSD and PWTD was signiﬁcantly decreased by anti-
thyroid medical treatment.
The left ventricular mass (LVM) was increased before treat-
ment compared to the control group and although decreased
after treatment yet the differences were insigniﬁcant. The left
ventricular mass and dimension revealed signiﬁcant changes
together with the left ventricular systolic and diastolic func-
tions in comparison to the control group. The LV diastolic
functions; were signiﬁcantly ameliorated with antithyroid
treatment together with peak E velocity, peak A velocity, dec-
laration time (DT) and isovolumic relation T (IVRT) (Table 5).
The correlation between serum antiapoptotic (Bcl-2) and
LV diastolic function was stressed upon. Before treatment,
the peak E velocity, the peak A velocity, the DT and IVRT
were signiﬁcantly correlated with Bcl-2 level, but after treat-
ment signiﬁcant correlation was only related to peak E and
A velocity and IVRT. The DT was insigniﬁcantly changed
Table 5 Echocardiographic ﬁndings in Graves’ thyrotoxicosis patients before and after treatment.
Parameter (mean ± SD) Control (C) Before ttt (B) After ttt (A) P
C vs B
P
C vs A
P
B vs A
LV systolic function
Fractional shortening (FS%) 39.32 ± 4.03 44.1 ± 11.1 39.98 ± 0.2 0.035 0.373 0.046
Ejection fraction (EF%) 74 ± 18.1 81.01 ± 1.1 77.97 ± 6.18 0.038 0.26 0.010
Stroke volume (SV) (ml/beat) 74 ± 10.6 84.13 ± 52.43 70.9 ± 26.88 0.032 0.558 0.044
Cardiac output (COP) (l/min) 5.2 ± 1.2 8.99 ± 1.6 5.87 ± 2.2 <0.001 0.14 <0.001
Cardiac index (CI) (l/min/m2) 3.3 ± 2.1 6.11 ± 3.12 3.8 ± 1.6 <0.001 0.30 <0.001
Peripheral vascular resistance PVR (dyne.sx cm5) 1521.2 ± 261.1 1089.41 ± 445.1 1399.9 ± 211.1 <0.001 0.052 <0.001
Correlated mean velocity of circumferential ﬁber
shortening (MVCFc) (circ/s)
1.2 ± 0.19 1.4 ± 0.2 1.19 ± 0.20 <0.001 0.84 <0.001
End- systolic wall stress (ESWS) (103 dyn/cm2) 54.9 ± 5.1 63 ± 1.1 58.1 ± 11.1 <0.001 0.156 0.01
LV dimensions and mass
End diastolic diameter EDD (cm) 4.7 ± 0.4 4.5 ± 0.5 4.6 ± 0.4 0.92 0.33 0.39
End systolic diameter (ESD) (cm) 2.8 ± 0.4 2.5 ± 1.1 2.6 ± 0.8 0.16 0.22 0.68
Interventricular septum thickness at diastole
(IVSD) (cm)
0.72 ± 0.10 0.82 ± 0.01 0.78 ± 0.1 0.017 0.023 0.033
Posterior wall thickness at diastole (PWTD) (cm) 0.85 ± 0.10 0.97 ± 0.2 0.89 ± 0.02 0.018 0.035 0.033
Left ventricular mass (LVM) (g) 112.6 ± 11.2 150 ± 77.3 135 ± 60.1 0.011 0.045 0.404
Left ventricular mass index (LVMI) (g) 80.6 ± 50.9 105.90 ± 30.7 83.9 ± 50.1 0.023 0.801 0.044
LV diastolic function
Peak E velocity (cm/s) 74.9 ± 15.8 67.9 ± 8.9 73.9 ± 9.5 0.038 0.767 0.014
Peak A velocity (cm/s) 51 ± 3.1 53.9 ± 1.1 52.9 ± 1.8 <0.001 0.131 0.011
Declaration time (DT) (ms) 170.5 ± 4.1 181.8 ± 11.2 170.6 ± 3.5 <0.001 0.919 <0.001
Isovolumic relaxation time (IVRT) (ms) 54.7 ± 2.5 84. 9 ± 18.1 68.6 ± 16.2 <0.001 <0.001 <0.001
Table 6 Correlation between thyroid hormones & TSH levels and serum Bcl-2 in Graves’ thyrotoxic patients before and after
treatment.
Serum Bcl-2 before ttt Serum Bcl-2 after ttt P
Serum free T3 Before ttt r= 0.186 NS
After ttt r= 0.101 NS
Serum freeT4 Before ttt r= 0.009 NS
After ttt r= 0.393 <0.01
Serum TSH Before ttt r= 0.026 NS
After ttt r= 0.053 NS
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TSH and serum Bcl-2 before and after treatment revealed sig-
niﬁcant correlation only with FT4 (Table 6).
6. Discussion
Apoptosis; one of the forms of programed cell death is a phys-
iological occurrence and is a requisite to the correct function-
ing of every organ.16,17 The signal to apoptosis can be started
practically in any cell of any organ. Disturbance of apoptosis
regulation determine the essential link of pathogenesis of many
diseases including the studied cases of autoimmune Graves’
toxicosis.
Thyroid disorders including subclinical toxicosis are becom-
ing very common. Fortunately they can be easily diagnosed and
treated, thus arresting cardiac changes and apoptosis. In the
present study, the cardiovascular changes in GT were detected
clinically, also by ECG and echocardiography (Tables 1, 3 and
5). Poulsen and coworkers, 200118 reported that echocardiogra-
phy has become a well established practical and safe non inva-
sive maneuver for diagnosing cardiovascular dysfunction.The electrocardiographic changes (Table 3) revealed signif-
icant sinus tachycardia, voltage changes for LVH, prolonged
QTc, increased QTcd before treatment and signiﬁcant
improvement after restoration of euthyroidism. The QTc was
signiﬁcantly longer in the studied cases of GT in comparison
to the control group before and after treatment thus conﬁrm-
ing the ﬁndings of Etinarslan et al. 1998.19 QTd >80 ms in the
present study before treatment and its signiﬁcant improvement
after restoration of euthyroidism may indicate regional inho-
mogeneity of ventricular repolarization time.20 The present
electrocardiographic changes are in agreement with the ﬁnding
of Lambardi, 199821 who reported that for the QTc intervals
and QTd, the smaller the better. The prolonged QTc and the
increased occurrence of QTd may be due to the shift of sympa-
thetic predominance and/or reduced vagal modulation which
are constant phenomena of thyrotoxicosis.22
The echocardiographic changes (Table 5) are in agreement
with Ching et al. 199623 who described cardiac hypertrophy as
a result of thyrotoxicosis and/or long term thyroxine therapy.
Cardiac remodeling involves increased rates of cardiomyocyte
cell death that precedes HF.24 The serum antiapoptotic marker
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comparison to the control group and was markedly diminished
after antithyroid treatment (Table 2). The expression of anti-
apoptotic molecules (Bcl-2) is regulated in thyroid cells to
avoid apoptotic cell death25 and there is up regulation of
antiapoptotic molecules (Bcl-2) protecting thyrocytes from
apoptotic cell death.26
Bcl-2, the ﬁrst example of an oncogene that inhibits cell
death rather than promoting cell proliferation, was found in
follicular lymphoma and is frequently linked to an immuno-
globulin by chromosome location.25 A correlation between ser-
um antiapoptotic Bcl-2 level and LV diastolic dysfunction
before and after antithyroid treatment was evident (Table 4).
Before treatment, the peak E velocity, the peak A velocity,
the DT and IVRT revealed signiﬁcant correlation with Bcl-2
level. However after restoration of euthyroidism the signiﬁcant
negative correlation was only related to peak A velocity and
IVRT.
In the present work beta blocker (propranolol) was com-
bined with carbimazole but ACE inhibitors were not used.
This could explain the relatively common persistence of fea-
tures of remodeling in the present study. Previous studies
showed that metoprolol, carvedilol over a time course of 3–
18 months led to regression of cardiac hypertrophy and dilata-
tion with progressive increase in EF and restoration of a more
elliptical chamber shape.27–29 Novel pharmacological ap-
proaches for reverse remodeling in heart failure have been
developed by pharmacological blockade of the sarcolemmal
Na/hydrogen exchanger.30
The anti apoptotic function of Bcl-2 differs and may be
stimulus dependent31 or cell speciﬁc.32 The anti apoptotic
Bcl-2 had a positive consequence on the viability of ischemia
of the brain and myocardium although it was believed to exert
minimal or no detectable changes in these organs.33 Salmaso
and coworkers (2002)34 found that Bcl-2 promoted hypertro-
phy in thyroid cells while attenuating the heart muscle cell.
7. Conclusion
Structural and functional cardiac changes are common ﬁnd-
ings in Graves’ toxicosis that can lead to many apoptotic
changes including diastolic and systolic dysfunction and car-
diac hypertrophy. Early diagnosis and prompt treatment of
Graves’ toxicosis can halt these cardiovascular changes. Search
for anti apoptotic measures is awaited.
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